<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610892</url>
  </required_header>
  <id_info>
    <org_study_id>D4920C00002</org_study_id>
    <nct_id>NCT04610892</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction</brief_title>
  <acronym>GOLDILOX</acronym>
  <official_title>A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrombolysis in Myocardial Infarction (TIMI) Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in&#xD;
      Participants with a Prior Myocardial Infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IIB, proof-of-concept, dose-range finding clinical study is being conducted to&#xD;
      evaluate the anti-inflammatory potential of MEDI6570 and its effect on surrogates for&#xD;
      atherosclerotic and heart failure (HF) events in patients with a history of myocardial&#xD;
      infarction (MI). The results of the Phase IIB study will inform future clinical development&#xD;
      options and precision medicine strategy for future clinical studies.&#xD;
&#xD;
      Participants will be randomized in a 3:3:3:1:1:1 ratio, with 198 participants in each of the&#xD;
      3 MEDI6570 groups and 198 participants across the 3 placebo groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non Calcified Plaque Volume</measure>
    <time_frame>9 months</time_frame>
    <description>Change in non-calcified plaque volume in the most diseased coronary segment (NCPVMD), as measured by CTA imaging compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT proBNP</measure>
    <time_frame>9 months</time_frame>
    <description>Change in NT proBNP compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>9 months</time_frame>
    <description>Change in LVEF as measured by echocardiography compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Longitudinal Strain (GLS)</measure>
    <time_frame>9 months</time_frame>
    <description>Change in GLS as measured by echocardiography compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global non-calcified plaque volume</measure>
    <time_frame>9 months</time_frame>
    <description>Change in Global non-calcified plaque volume as measured by CTA imaging compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low attenuation plaque volume</measure>
    <time_frame>9 months</time_frame>
    <description>Change in Low attenuation plaque volume as measured by CTA imaging compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat attenuation Index (FAI)</measure>
    <time_frame>9 months</time_frame>
    <description>Change in FAI as measured by CTA imaging compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events as a measure of safety and tolerability of MEDI6570</measure>
    <time_frame>13.5 months</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as a measure of safety and tolerability of MEDI6570</measure>
    <time_frame>13.5 months</time_frame>
    <description>Adverse events (AEs) as evaluated by incidence of clinically important changes in vital signs, ECG, chemistry, or hematology values compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Immunogenicity</measure>
    <time_frame>13.5 months</time_frame>
    <description>Immunogenicity as measured by anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 Cmax</measure>
    <time_frame>13.5 months</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 Terminal Half-life</measure>
    <time_frame>13.5 months</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>9 months</time_frame>
    <description>Change in LVEF as measured by echocardiography among participants with reduced ejection fraction compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Longitudinal Strain (GLS)</measure>
    <time_frame>9 months</time_frame>
    <description>Change in GLS as measured by echocardiography among participants with reduced ejection fraction compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA titer</measure>
    <time_frame>13.5 months</time_frame>
    <description>Immunogenicity as measured by anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">792</enrollment>
  <condition>Coronary Heart Disease (CHD)</condition>
  <arm_group>
    <arm_group_label>MEDI6570 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly Subcutaneous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6570 Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly Subcutaneous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6570 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly Subcutaneous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Low dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly Subcutaneous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Medium dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly Subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo High dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly Subcutaneous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6570</intervention_name>
    <description>MEDI6570</description>
    <arm_group_label>MEDI6570 High dose</arm_group_label>
    <arm_group_label>MEDI6570 Low dose</arm_group_label>
    <arm_group_label>MEDI6570 Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Buffer</description>
    <arm_group_label>Placebo High dose</arm_group_label>
    <arm_group_label>Placebo Low dose</arm_group_label>
    <arm_group_label>Placebo Medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must provide informed consent before any study specific activities are&#xD;
             performed, must be able and willing to meet all requirements for randomization within&#xD;
             42 days after signing the full ICF, and must adhere to the schedules of activities.&#xD;
&#xD;
          2. Participant must be ≥ 40 years of age at the time of signing the ICF.&#xD;
&#xD;
          3. Participant must:&#xD;
&#xD;
               1. be 30 to 365 days after presumed type-1 (ie, due to plaque rupture or erosion) MI&#xD;
                  (either STEMI or NSTEMI) at the time of enrollment.&#xD;
&#xD;
               2. have persistent inflammation, defined as hs CRP ≥ 1 mg/L, as measured centrally&#xD;
                  at screening Visit 1.&#xD;
&#xD;
          4. Participant must have body mass index within the range 18 to 40 kg/m2 inclusive.&#xD;
&#xD;
          5. For female participants, the participant must not be pregnant or lactating and must be&#xD;
             of non-childbearing potential, confirmed at screening Visit 1 by one of the following:&#xD;
&#xD;
               1. Postmenopausal, defined as amenorrhea for ≥ 12 months following cessation of all&#xD;
                  exogenous hormonal treatments, and with luteinizing hormone and follicle&#xD;
                  stimulating hormone levels in the postmenopausal range.&#xD;
&#xD;
               2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral&#xD;
                  oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as&#xD;
                  irreversible surgical sterilization.&#xD;
&#xD;
          6. Participant must have an evaluable, pre-randomization CTA with quantifiable, non&#xD;
             calcified plaque, as confirmed by the core laboratory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any clinically important disease or disorder which, in the opinion of the&#xD;
             investigator, may either put the participant at risk because of participation in the&#xD;
             study, or influence the results or the participant's ability to participate in the&#xD;
             study.&#xD;
&#xD;
          2. Percutaneous coronary intervention [PCI] planned after screening Visit 1. Eligible&#xD;
             participants who have a PCI planned after screening may be rescreened after the PCI&#xD;
             has been performed.&#xD;
&#xD;
          3. History of or planned coronary artery bypass grafting.&#xD;
&#xD;
          4. Documented episode of post-MI pericarditis in the 3 months before enrollment.&#xD;
&#xD;
          5. Ongoing New York Heart Association Class IV (severe) HF.&#xD;
&#xD;
          6. Increased risk of bleeding&#xD;
&#xD;
               1. Patients with history or presence of any bleeding disorder.&#xD;
&#xD;
               2. Active bleeding or high risk for major bleeding (eg, gastrointestinal pathology,&#xD;
                  malignancy with high risk of bleeding, active peptic ulcer).&#xD;
&#xD;
               3. Need for chronic anticoagulation therapy (prophylactic doses of heparin are&#xD;
                  allowed).&#xD;
&#xD;
               4. Known severe liver disease (eg, ascites and/or clinical signs of coagulopathy).&#xD;
&#xD;
          7. History or presence of any of the following:&#xD;
&#xD;
               1. Ongoing infection or febrile illness that in the opinion of the investigator may&#xD;
                  be the cause of elevated hs-CRP on screening.&#xD;
&#xD;
               2. Ongoing atrial fibrillation or flutter.&#xD;
&#xD;
               3. Cancer within 5 years before randomization, with the exception of non melanoma&#xD;
                  skin cancer.&#xD;
&#xD;
               4. Alcohol or substance abuse within 6 months before randomization, as judged by the&#xD;
                  investigator.&#xD;
&#xD;
               5. Known history of hypersensitivity reactions to other biologics, to human IgG&#xD;
                  preparations, or to any component of MEDI6570, or ongoing severe allergy as&#xD;
                  judged by the investigator.&#xD;
&#xD;
               6. Patients with active positive results on screening for serum hepatitis B surface&#xD;
                  antigen, hepatitis C antibody, or HIV.&#xD;
&#xD;
          8. Any clinically important abnormalities in clinical chemistry, hematology, coagulation&#xD;
             parameters, as judged by the investigator, including but not limited to:&#xD;
&#xD;
          9. Blood pressure (BP) values at screening:&#xD;
&#xD;
               1. Systolic BP &lt; 90 mmHg or &gt; 180 mmHg.&#xD;
&#xD;
               2. Diastolic BP &gt; 100 mmHg.&#xD;
&#xD;
               3. Participants who are excluded based on elevated BP may be rescreened following&#xD;
                  adequate treatment.&#xD;
&#xD;
         10. Participants with any of the following contraindications to CTA:&#xD;
&#xD;
               1. eGFR &lt; 50 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration&#xD;
                  equation, or end stage renal disease treated with kidney transplant or renal&#xD;
                  replacement therapy.&#xD;
&#xD;
               2. Allergy to iodinated contrast.&#xD;
&#xD;
               3. History of contrast-induced nephropathy.&#xD;
&#xD;
               4. Contraindication to nitroglycerin.&#xD;
&#xD;
               5. Rapid heart rate that is uncontrolled by medical therapy.&#xD;
&#xD;
               6. Inability to hold breath for at least 6 seconds.&#xD;
&#xD;
         11. Receipt of any investigational device or therapy within 6 months or 5 half lives&#xD;
             before screening (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325-4139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500-05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liberec</city>
        <zip>46002</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cona</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>670-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasuga-shi</city>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasugai-shi</city>
        <zip>487-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyushu-shi</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-Shi</city>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minami-ku</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miyazaki-shi</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1814 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-095</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-423</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-082</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opole</city>
        <zip>45-401</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Włoclawek</city>
        <zip>87-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hospitalet de Llobregat(Barcel</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontevedra</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

